Revolutionizing CAR-T Cell Therapies: Lyell Immunopharma’s Heartfelt Acquisition of ImmPACT Bio and Prioritization of Next-Generation Pipeline
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 Lyell Immunopharma, Inc. Acquires ImmPACT Bio USA Inc. Exciting Developments in CAR T-Cell Therapy Lyell Immunopharma, Inc. (Nasdaq: LYEL) has made a significant announcement today regarding its acquisition of ImmPACT Bio USA Inc., a clinical-stage biotechnology company. The acquisition includes ImmPACT’s lead program, IMPT-314, a revolutionary CD19/20-targeting chimeric…